Blog

David Sebag: The first patient was randomised in the ARTEMIS organ preservation phase II rectal cancer trial at Leeds Teaching Hospitals

Photo taken from David Sebag-Montefiore/LinkedIn

Apr 1, 2024, 09:54

David Sebag: The first patient was randomised in the ARTEMIS organ preservation phase II rectal cancer trial at Leeds Teaching Hospitals

David Sebag, Professor of Clinical Oncology and Health Research at University of Leeds, shared on X:

“Fantastic news! Following last week’s brilliant hybrid workshop at University of Leeds, the first patient was randomised in the ARTEMIS organ preservation phase II rectal cancer trial at Leeds Teaching Hospitals today!
Huge congrats to the team!

ARTEMIS will test the benefits of adding Adlai Nortye AN0025 to short course and long course CRT. It is a selective inhibitor of EP4, one of four PGE2 receptors, a strong pre-clinical rationale and a high CR rate in early phase.
doi: 10.1016/j.radonc.2023.109669

You can read more about this study here.”

Source: David Sebag/X

Adlai Nortye ARTEMIS cancer CRT David Sebag Leeds Teaching Hospitals OncoDaily Oncology PGE2 receptors rectal cancer selective inhibitor of EP4 Trial University of Leeds

Immunotherapy for Melanoma: Types, Success Rate, Side Effects & More

Tom Green and Testicular Cancer: How He Went Against, How He Survived, and More

Steven O'Day: At the Forefront of Immunotherapy

Dennis Slamon was honored with the 2024 Szent-Györgyi Prize for Progress in Cancer Research

Pfizer is partnering with Patrick Dempsey in support of the American Cancer Society initiative 'Change the Odds'

Special Coverage